Executive Summary
Rating: HOLD | ISRG
Intuitive Surgical’s appeal is straightforward: a dominant installed base, recurring instrument and service revenue, and a debt-free balance sheet that supports continued reinvestment and buybacks. The investment case is anchored by Q1 2026 revenue of $2,770.8M, EBITDA of $1,055.3M, and levered free cash flow of $2,254.1M on a TTM basis. The main risk is valuation, with the stock trading at 37.8x EV/EBITDA and 50.8x trailing P/E, leaving limited room for execution missteps. The near-term catalyst is continued procedure growth and system placements outside China, where tender disruption remains the clearest operating overhang.
Investment Rating
Rating: HOLD
Valuation is rich at 37.8x EV/EBITDA and 35.4x forward P/E, but supported by $3,360.8M of TTM operating cash flow and $2,254.1M of TTM levered free cash flow. The company has 0.0 of total debt and a 4.6 current ratio, which preserves flexibility, but the shares already discount durable premium execution. Upside depends on sustained procedure growth and a cleaner China backdrop.
Company Profile
Intuitive Surgical develops and sells robotic-assisted surgical systems, with revenue generated from capital system placements, recurring instruments and accessories, and service contracts. Its core platform is the da Vinci system, complemented by Ion, stapling, energy, and digital analytics products. The company operates in 29 countries, with 68.0% of 2025 revenue from the U.S. and 32.0% from outside the U.S. Manufacturing is concentrated in the U.S., Mexico, China, Bulgaria, and Germany, and the listed equity class is common stock on Nasdaq.
Economic Moat
Business Model
The moat is built on recurring utilization rather than one-time system sales. Each installed da Vinci system creates a multi-year revenue stream through instruments, accessories, service, software, and training, which makes the platform sticky once hospitals standardize on it. The company also reinforces adoption through field engineers, proctoring, SimNow, and My Intuitive tools. More than 5,600.0 granted patents and 2,500.0 pending patents worldwide as of FY2025 add intellectual-property protection, while the integrated product stack raises switching costs for hospitals already committed to the platform.
Risk Factors
China tender delays and pricing controls are the highest-severity risk. The company said July 2023 anti-corruption scrutiny led to tenders being canceled or delayed without a timeline, and fewer systems were placed in China than anticipated in 2025. Usage-based leases and customer financing are a medium-severity risk because revenue depends on utilization and collections; if usage falls short, the company may not recover its costs. Single-source supply and Mexico manufacturing concentration are a high-severity risk, especially given rare earth export controls from China in 2025 that could disrupt supply. FDA and EU regulatory non-compliance is also a high-severity risk, because an adverse finding could delay imports or block CE marking and EU sales.
Management Discussion & Analysis
Management is signaling continued reinvestment rather than balance-sheet optimization. Share repurchases totaled $2.3B in 2025 for 4.8M shares, while cash and investments rose to $9.0B at December 31, 2025. That combination suggests buybacks remain opportunistic and funded from operating cash flow rather than leverage. Management also expects R&D to continue increasing after spending $1.3B in 2025, and depreciation to rise in 2026 following prior manufacturing buildout. Tariffs added $63.0M to 2025 cost of revenues and are expected to increase again in 2026, which is the clearest near-term cost headwind.
Recent Earnings
Q1 2026 showed that the installed base is still monetizing well, even with a modest sequential revenue decline. Revenue was $2,770.8M, up 23.0% year over year from $2,253.4M in Q1 2025, while EBITDA rose 45.0% to $1,055.3M from $727.7M. The sequential decline from $2,866.2M in Q4 2025 to $2,770.8M in Q1 2026 has no clear driver identified; investors should seek further disclosure. The key takeaway is that EBITDA is growing faster than revenue, which points to operating leverage and strong unit economics.
Financial Analysis
Growth
ISRG — Financial Growth (Quarterly, USD Mil)
Source: Yahoo Finance — Quarterly Financial Statements
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|---|
| REVENUE (USD Mil) | 2,253.400 | 2,440.000 | 2,505.100 | 2,866.200 | 2,770.800 |
| EBIT (USD Mil) | 578.100 | 743.400 | 759.700 | 864.300 | 855.300 |
| EBITDA (USD Mil) | 727.700 | 890.000 | 919.700 | 1,085.200 | 1,055.300 |
| NET INCOME (USD Mil) | 698.400 | 658.400 | 704.400 | 794.800 | 821.500 |
| DILUTED EPS | 1.920 | 1.810 | 1.950 | 2.210 | 2.280 |
Revenue reached $2,770.8M in Q1 2026, up 23.0% year over year, while EBITDA increased to $1,055.3M, up 45.0% year over year. Net income also improved to $821.5M from $698.4M in Q1 2025. The main analytical point is not the quarter-to-quarter sequence, but that earnings are expanding faster than sales, indicating favorable mix and operating leverage.
Profitability
ISRG — Profitability (TTM)
Source: Yahoo Finance — Trailing Twelve Months (TTM)
| Metric | TTM |
|---|---|
| Operating Margin (TTM) | 30.9% |
| Net Margin (TTM) | 28.2% |
| Return on Assets (TTM) | 10.2% |
| Return on Equity (TTM) | 17.2% |
TTM operating margin was 30.9%, net margin was 28.2%, return on assets was 10.2%, and return on equity was 17.2%. Those figures place Intuitive Surgical among the more profitable large-cap medtech names and show that the business converts revenue into earnings efficiently. The margin profile is materially stronger than most peers, with only Edwards Lifesciences posting a slightly higher operating margin in the comparable set.
Valuation
ISRG — Valuation Multiples
Source: Yahoo Finance
| Metric | Value |
|---|---|
| Market Cap (USD Mil) | 148,022.362 |
| Enterprise Value (USD Mil) | 146,694.816 |
| Trailing P/E | 50.784 |
| Forward P/E | 35.447 |
| Price/Sales (TTM) | 13.988 |
| Price/Book (mrq) | 8.476 |
| EV/Revenue | 13.863 |
| EV/EBITDA | 37.753 |
| Beta (5Y Monthly) | 1.453 |
Intuitive Surgical trades at 50.8x trailing P/E, 35.4x forward P/E, 14x price/sales, 13.9x EV/revenue, and 37.8x EV/EBITDA. The premium reflects a long-duration recurring revenue model, a large installed base, and above-peer profitability rather than near-term acceleration alone. The valuation is demanding, but it is supported by the company’s cash generation and balance-sheet strength.
Leverage
ISRG — Leverage & Coverage (Quarterly)
Source: Yahoo Finance — Quarterly Financial Statements
| Metric | Value |
|---|---|
| Total Debt/Equity % (mrq) | — |
| Current Ratio (mrq) | 4.610 |
| Total Debt (mrq, USD Mil) | 0.000 |
| Operating Cash Flow (TTM, USD Mil) | 3,360.800 |
| Levered Free Cash Flow (TTM, USD Mil) | 2,254.087 |
The balance sheet is effectively unlevered, with 0.0 of total debt and a 4.6 current ratio. Operating cash flow was $3,360.8M on a TTM basis, and levered free cash flow was $2,254.1M. That leaves the company with substantial financial flexibility and no refinancing burden. The leverage profile is therefore a source of resilience, not a constraint.
Comparable Analysis
On growth, Intuitive Surgical’s TTM revenue growth of 23.0% is well ahead of MDT at 9.9%, SYK at 2.6%, ZBH at 9.3%, SNN at 7.4%, and EW at 16.7%. On profitability, its 30.9% operating margin and 28.2% net margin exceed MDT, SYK, ZBH, and SNN, and are broadly in line with EW’s 31.2% operating margin and 17.4% net margin. On leverage, ISRG stands out with 0.0 debt and a 4.6 current ratio, while most peers carry meaningful debt. On valuation, the stock screens at a clear premium to the group, which is consistent with its stronger growth, profitability, and balance-sheet profile.
Growth
| Company | Revenue TTM (USD Mil) | Revenue Growth YoY % | EBITDA TTM (USD Mil) | Diluted EPS TTM |
|---|---|---|---|---|
| ISRG | 10,582.100 | 23.0% | 3,885.600 | 8.230 |
| MDT | 36,364.000 | 9.9% | 10,081.000 | 3.730 |
| SYK | 25,270.000 | 2.6% | 6,918.000 | 8.640 |
| ZBH | 8,409.100 | 9.3% | 2,581.000 | 3.860 |
| SNN | 6,164.000 | 7.4% | 1,336.000 | 1.430 |
| EW | 6,303.500 | 16.7% | 1,903.600 | 1.850 |
Valuation
| Company | Trailing P/E | Forward P/E | EV/Revenue | EV/EBITDA | Price/Sales (TTM) | Price/Book (mrq) | Market Cap (USD Mil) | Enterprise Value (USD Mil) | Beta (5Y Monthly) |
|---|---|---|---|---|---|---|---|---|---|
| ISRG | 50.784 | 35.447 | 13.863 | 37.753 | 13.988 | 8.476 | 148,022.360 | 146,694.820 | 1.453 |
| MDT | 21.718 | 12.638 | 3.442 | 12.415 | 2.860 | 2.122 | 104,007.520 | 125,151.890 | 0.597 |
| SYK | 36.038 | 18.614 | 5.249 | 19.174 | 4.724 | 5.312 | 119,365.120 | 132,648.120 | 0.785 |
| ZBH | 23.263 | 9.972 | 2.908 | 9.476 | 2.066 | 1.370 | 17,371.960 | 24,456.740 | 0.472 |
| SNN | 21.829 | 14.386 | 11.244 | 51.876 | 2.149 | 12.538 | 13,248.430 | 69,306.340 | 0.673 |
| EW | 46.681 | 25.644 | 7.525 | 24.920 | 7.889 | 4.825 | 49,726.090 | 47,436.930 | 0.866 |
Profitability
| Company | Operating Margin (TTM) | Net Margin (TTM) | Return on Assets (TTM) | Return on Equity (TTM) |
|---|---|---|---|---|
| ISRG | 30.9% | 28.2% | 10.2% | 17.2% |
| MDT | 21.3% | 13.2% | — | 9.9% |
| SYK | 17.8% | 13.2% | 7.7% | 15.2% |
| ZBH | 19.7% | 9.1% | 4.1% | 6.1% |
| SNN | 14.0% | 10.1% | 5.3% | 11.8% |
| EW | 31.2% | 17.4% | 8.3% | 10.5% |
Leverage
| Company | Total Debt/Equity % (mrq) | Current Ratio (mrq) | Total Debt (mrq, USD Mil) | Operating Cash Flow TTM (USD Mil) | Free Cash Flow TTM (USD Mil) |
|---|---|---|---|---|---|
| ISRG | — | 4.610 | 0.000 | 3,360.800 | 2,254.090 |
| MDT | 57.060 | — | 28,071.000 | 7,330.000 | — |
| SYK | 66.295 | 2.112 | 15,234.000 | 5,375.000 | 4,359.880 |
| ZBH | 59.827 | 1.733 | 7,587.000 | 1,673.700 | 1,044.120 |
| SNN | 62.904 | 2.572 | 3,327.000 | 1,285.000 | 876.630 |
| EW | 6.806 | 4.421 | 702.900 | 1,358.600 | 902.140 |
Returns
| Company | Return on Equity (TTM) | Return on Assets (TTM) |
|---|---|---|
| ISRG | 17.2% | 10.2% |
| MDT | 9.9% | — |
| SYK | 15.2% | 7.7% |
| ZBH | 6.1% | 4.1% |
| SNN | 11.8% | 5.3% |
| EW | 10.5% | 8.3% |
Source: Yahoo Finance
Conclusion
Intuitive Surgical remains a high-quality franchise with recurring revenue, strong operating leverage, and a debt-free balance sheet. The investment case is not about cheapness; it is about whether the company can keep compounding procedure volumes, system placements, and recurring consumables fast enough to justify a premium multiple. China remains the key operating risk, and the current valuation leaves little margin for disappointment. Even so, the combination of 23.0% Q1 2026 revenue growth, 45.0% EBITDA growth, and $2,254.1M of TTM levered free cash flow supports a constructive stance.
Data sourced from Yahoo Finance. Not investment advice.
Leave a Reply